Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.26m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 12 2349 7700Fax+44 12 2349 7701
- Websitehttps://sareum.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Genincode PLC | 1.72m | -6.73m |
Provexis plc | 598.08k | -496.59k |
Oncimmune Holdings PLC | 1.15m | -6.15m |
LungLife AI Inc | 36.62k | -4.31m |
Destiny Pharma PLC | 0.00 | -5.66m |
Verici DX PLC | 15.13k | -8.93m |
OptiBiotix Health PLC | 689.10k | -13.17m |
Skinbiotherapeutics PLC | 161.65k | -2.88m |
Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m |
Oxford Biodynamics PLC | 510.00k | -10.83m |
Sareum Holdings Plc | 0.00 | -4.26m |
Science in Sport PLC | 65.93m | -7.07m |
CRUSHMETRIC Group Ltd | 396.87k | -876.23k |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 2024 | 4.57m | 6.36% |
HSBC Global Asset Management (UK) Ltd.as of 01 Apr 2024 | 3.29m | 4.58% |
Jarvis Investment Management Ltd.as of 01 Apr 2024 | 1.20m | 1.67% |
IG Markets Ltd.as of 01 Apr 2024 | 420.00k | 0.59% |
Rowan Dartington & Co. Ltd. (Broker)as of 01 Apr 2024 | 172.00k | 0.24% |
Evelyn Partners Investment Management Services Ltd.as of 01 Apr 2024 | 117.00k | 0.16% |
KW Investment Management Ltd.as of 01 Apr 2024 | 108.00k | 0.15% |
iDealing.com Ltd.as of 01 Apr 2024 | 92.00k | 0.13% |
Eurizon Capital SGR SpAas of 01 Apr 2024 | 91.00k | 0.13% |
J. M. Finn & Co. Ltd.as of 01 Apr 2024 | 89.00k | 0.12% |